Mind Pharmaceuticals

Mind Pharma, a Yale IP–backed biotech, develops next-gen psychedelic treatments for psychiatric and CNS disorders. Focus: depression, migraine, and cluster headaches. Its short-acting model improves scalability, offering less frequent dosing than J&J’s Esketamine. Proof of concept studies completed in 48  participants and more than 100 patients underway at Yale.